Aradigm has announced positive top line results from a Phase IIb study of ciprofloxacin (ARD-3100) for inhalation in patients with non-cystic fibrosis bronchiectasis, a progressive lung disease.

The mutlicentre double-blind, and placebo-controlled trial randomised 95 patients into four groups, and showed a mean reduction in colony forming units per gram of sputum.

The drug was well-tolerated and no difference in adverse events was observed between the active and placebo groups.

Aradigm senior medical director Paul Bruinenberg said the 2ml dose of ARD-3100 is equipotent to the 3ml dose.